Metastatic renal cancer: real-world evidence from a large Italian claims database


  • Giulia Ronconi Fondazione ReS - Ricerca e Salute, Casalecchio di Reno, Bologna - Italy
  • Letizia Dondi Fondazione ReS - Ricerca e Salute, Casalecchio di Reno, Bologna - Italy
  • Carlo Piccinni Fondazione ReS - Ricerca e Salute, Casalecchio di Reno, Bologna - Italy
  • Silvia Calabria Fondazione ReS - Ricerca e Salute, Casalecchio di Reno, Bologna - Italy
  • Anna Capponcelli Fondazione ReS - Ricerca e Salute, Casalecchio di Reno, Bologna - Italy
  • Antonella Pedrini Fondazione ReS - Ricerca e Salute, Casalecchio di Reno, Bologna - Italy
  • Maurizio Marangolo Fondazione ReS - Ricerca e Salute, Casalecchio di Reno, Bologna - Italy
  • Immacolata Esposito Drugs & Health Srl, Roma - Italy
  • Carmine Pinto Struttura Complessa di Oncologia, IRCCS Santa Maria Nuova, Reggio Emilia - Italy
  • Nello Martini Fondazione ReS - Ricerca e Salute, Casalecchio di Reno, Bologna - Italy



Big Data, Health Care Costs, Italian National Health Service, Public Health Practice, Renal Neoplasms


Purpose: To assess the healthcare resources’ consumption and integrated costs of patients with renal cancer and new metastasis (mRCC), in the perspective of the Italian National Health System (NHS).

Methods: From the ReS database, through the administrative data record linkage, adults with a primary/secondary hospital (ordinary/daily admissions) diagnosis (ICD9-CM code) of renal cancer and lymph node and/or distant metastases in the same hospital discharge (index date) were selected in 2015. Metastases were defined new if they were absent in the 2 previous years. Patients were described in terms of gender, age (mean ± SD) and comorbidities of interest. The 2-year survival and annual pharmacological treatments, hospitalization, outpatient specialist services and costs were analysed.

Results: Out of >6 million adults in the 2015 ReS database, 133 (2.1 × 100,000) were hospitalized with a diagnosis of RCC and metastasis. Patients with new metastases were 63.2% (1.4 × 100,000; 73.8% males; mean age 68 ± 13). Hypertension was the most common comorbidity (70.2% of mRCC patients). The 2-year survival of mRCC patients was 26.2%. During 1-year follow-up, at least a drug was prescribed to 88.1% of mRCC patients (on average € 12,095/patient), 91.7% were hospitalized (€ 8,897/patient) and 82.1% entrusted the outpatient specialist care (€ 1,075/patient). The mean overall expenditure for the NHS was € 22,067 per capita.

Conclusions: This study shows the mRCC burden on the Italian real clinical practice and its economic impact in the perspective of the NHS. Real-world analyses prove to be useful to concretely estimate the overall healthcare responsibility on patients affected by mRCC.


Download data is not yet available.


Porta C, D’Attino R. Epidemiologia e standard di cura attuale del carcinoma renale metastatico in Italia. Ital J Public Health. 2011;8(3)(suppl 2):S7-S16.

Ljungberg B, Campbell SC, Choi HY, et al. The epidemiology of renal cell carcinoma. Eur Urol. 2011;60(4):615-621. PMID:21741761

Unverzagt S, Moldenhauer I, Nothacker M, et al. Immunotherapy for metastatic renal cell carcinoma. Cochrane Database Syst Rev. 2017;5(5):CD011673. PMID:28504837

Zerdes I, Tolia M, Tsoukalas N, et al. Systemic therapy of metastatic renal cell carcinoma: review of the current literature. Urologia. 2019;86(1):3-8. PMID:30270773

Nazha S, Tanguay S, Kapoor A, et al. Use of targeted therapy in patients with metastatic renal cell carcinoma: clinical and economic impact in a Canadian real-life setting. Curr Oncol. 2018;25(6):e576-e584. PMID:30607126

Goebell PJ, Staehler M, Müller L, et al; RCC-Registry Group (Tumour Registry of Advanced Renal Cell Carcinoma). Changes in Treatment Reality and Survival of Patients With Advanced Clear Cell Renal Cell Carcinoma - Analyses From the German Clinical RCC-Registry. Clin Genitourin Cancer. 2018;16(6):e1101-e1115. PMID:30061035

de Groot S, Redekop WK, Versteegh MM, et al. Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma. Qual Life Res. 2018;27(1):115-124. PMID:28917029

Atkins MB, Tannir NM. Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma. Cancer Treat Rev. 2018;70:127-137. PMID:30173085

Associazione Italiana di Oncologia Medica. Linee Guida. Tumori del rene. 2018. Online (

Associazione Italiana dei Registri Tumori. I numeri del cancro in Italia. 2019. Online (

Lipworth L, Morgans AK, Edwards TL, et al. Renal cell cancer histological subtype distribution differs by race and sex. BJU Int. 2016;117(2):260-265. PMID:25307281

Escudier B, Porta C, Schmidinger M, et al; ESMO Guidelines Committee. Electronic address: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019;30(5):706-720. PMID:30788497

Manola J, Royston P, Elson P, et al; International Kidney Cancer Working Group. Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. Clin Cancer Res. 2011;17(16):5443-5450. PMID:21828239

Pal S, Gong J, Mhatre SK, et al. Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database. BMC Cancer. 2019;19(1):548. PMID:31174493

Posadas EM, Limvorasak S, Figlin RA. Targeted therapies for renal cell carcinoma. Nat Rev Nephrol. 2017;13(8):496-511. PMID:28691713

Choueiri TK, Motzer RJ. Systemic Therapy for Metastatic Renal-Cell Carcinoma. N Engl J Med. 2017;376(4):354-366. PMID:28121507

Network NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Kidney Cancer. Version 1.2020-June 7, 2019. 2020. Online

Dickman PW, Hakulinen T, Luostarinen T, et al. Survival of cancer patients in Finland 1955-1994. Acta Oncol. 1999;38(suppl 12):1-103. PMID:10225326

Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17(8):2530-2540. PMID:10561319

Tenold M, Ravi P, Kumar M, et al. Current Approaches to the Treatment of Advanced or Metastatic Renal Cell Carcinoma. Am Soc Clin Oncol Educ Book. 2020;40:1-10. PMID: 32239988

Dutcher JP, Flippot R, Fallah J, Escudier B. On the Shoulders of Giants: The Evolution of Renal Cell Carcinoma Treatment-Cytokines, Targeted Therapy, and Immunotherapy. Am Soc Clin Oncol Educ Book. 2020;40:1-18. PMID: 32243201

Calabria S, Forcesi E, Dondi L, Pedrini A, Maggioni AP, Martini N. Target Population of Non-deferrable Surgery and Uncontrolled Severe Bleeding Related to Dabigatran. Cardiovasc Drugs Ther. 2018;32(3):281-286. PMID:29869189

Cimminiello C, Dondi L, Pedrini A, et al. Patterns of treatment with antiplatelet therapy after an acute coronary syndrome: data from a large database in a community setting. Eur J Prev Cardiol. 2019;26(8):836-846. PMID:30477319

Piccinni C, Ronconi G, Calabria S, et al. Healthcare resources utilisation in primary progressive multiple sclerosis. Neurol Sci. 2018;39(7):1169-1174. PMID:29637449

Collaborating Center for Drug Statistics Methodology (WHO). ATC/DDD Index 2020. Online (

Ministero del Lavoro, della Salute e delle Politiche Sociali. Classificazione delle malattie, dei traumatismi, degli interventi chirurgici e delle procedure dagnostiche e terapeutiche. Versione italiana dell’ICD9-CM. 2007. Online (

Ministero del Lavoro, della Salute e delle Politiche Sociali. Nomenclatore prestazioni di assistenza specialistica ambulatoriale. Allegato 4. DPCM 12 gennaio 2017. 2017. Online (

Istituto Nazionale di Statistica, ISTAT. Resident population by age, sex and marital status. 2015. Online (

Edwards SJ, Wakefield V, Cain P, et al. Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation. Health Technol Assess. 2018;22(6):1-278. PMID:29393024

Boffa DJ, Mallin K, Herrin J, et al. Survival After Cancer Treatment at Top-Ranked US Cancer Hospitals vs Affiliates of Top-Ranked Cancer Hospitals. JAMA Netw Open. 2020;3(5):e203942. PMID:32453382

Agenzia Italiana del Farmaco. L'uso dei farmaci in Italia. Rapporto Nazionale Anno 2018 [The use of drugs in Italy. National Report Year 2018]. 2018. Online (

Ljungberg B, Albiges L, Bensalah K, et al. EAU Renal Cell Carcinoma Guidelines 2020. Online (

Additional Files



How to Cite

Ronconi, G., Dondi, L., Piccinni, C., Calabria, S., Capponcelli, A., Pedrini, A., Marangolo, M., Esposito, I., Pinto, C., & Martini, N. (2021). Metastatic renal cancer: real-world evidence from a large Italian claims database. Global and Regional Health Technology Assessment, 8(1), 1–7.



Original Research Articles


Received 2020-08-06
Accepted 2020-12-15
Published 2021-02-05


Most read articles by the same author(s)